Benzinga | Sep 10, 2020 07:34AM EDT

Soligenix Announces Investor Webcast Event And Presentation Today Titled 'Advantages of the CiVax Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine'

PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ --Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, released the presentation for its Investor Webcast event today from 4:00 -- 5:00 pm Eastern Time on the use of its thermostabilized glycoprotein vaccine platform for the development of a COVID-19 vaccine, called CiVax(tm).

The development of CiVax(tm)is based on the thermostabilized glycoprotein vaccine platform which Soligenix has been developing in collaboration with the University of Hawaii at Mnoa, focused on multivalent thermostabilized vaccines for filovirus infections such as Ebola.